Effects of atorvastatin on human C-reactive protein metabolism

Atherosclerosis

Volumn 226, Issue 2, 2013, Pages 466-470

  Thongtang, Nuntakorn ^a,b   Diffenderfer, Margaret R ^a   Ooi, Esther M M ^a,c   Asztalos, Bela F ^a   Dolnikowski, Gregory G ^a   Lamon Fava, Stefania ^a   Schaefer, Ernst J ^a  

^a TUFTS UNIVERSITY   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Atorvastatin; C reactive protein; Lipoprotein; Metabolism

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; LEUCINE; PLACEBO;

AFFINITY CHROMATOGRAPHY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; FEMALE; GAS CHROMATOGRAPHY; HUMAN; HYPERLIPIDEMIA; KINETICS; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ISOLATION; PROTEIN METABOLISM; RANDOMIZED CONTROLLED TRIAL;

C-REACTIVE PROTEIN; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; KINETICS; MALE; MIDDLE AGED; PYRROLES;

EID: 84872410105     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.11.012     Document Type: Article

References (34)

1. Pepys M.B., Hirschfield G.M. C-reactive protein: a critical update. J Clin Invest 2003, 111:1805-1812.
2. Danesh J., Collins R., Appleby P., Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998, 279:1477-1482.
3. Pai J.K., Pischon T., Ma J., et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004, 351:2599-2610.
4. Genest J. C-reactive protein: risk factor, biomarker and/or therapeutic target?. Can J Cardiol 2010, 26(Suppl. A):41A-44A.
5. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511.
6. Kaptoge S., Di Angelantonio E., Lowe G., et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010, 375:132-140.
7. Quist-Paulsen P. Statins and inflammation: an update. Curr Opin Cardiol 2010, 25:399-405.
8. Asher J., Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich) 2007, 9:622-628.
9. Biasucci L.M., Biasillo G., Stefanelli A. Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance. Clin Chem Lab Med 2010, 48:1685-1691.
10. Ridker P.M., Rifai N., Clearfield M., et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001, 344:1959-1965.
11. Ridker P.M., Rifai N., Pfeffer M.A., et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998, 98:839-844.
12. Ridker P.M., Danielson E., Fonseca F.A., et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009, 373:1175-1182.
13. Martinez V.B., Gonzalez-Juanatey J.R. Markers of inflammation and cardiovascular disease: clinical applications of C-reactive protein determination. Am J Cardiovasc Drugs 2009, 9(Suppl. 1):3-7.
14. Gensini G.F., Gori A.M., Dilaghi B., et al. Effect of atorvastatin on circulating hsCRP concentrations: a sub-study of the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study. Int J Cardiol 2010, 142:257-264.
15. Thongtang N., Ai M., Otokozawa S., et al. Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. Am J Cardiol 2011, 107:387-392.
16. Bonnet J., McPherson R., Tedgui A., et al. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clin Ther 2008, 30:2298-2313.
17. Lamon-Fava S., Diffenderfer M.R., Barrett P.H., et al. Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism. J Lipid Res 2007, 48:1746-1753.
18. McNamara J.R., Schaefer E.J. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin Chim Acta 1987, 166:1-8.
19. Cobelli C., Toffolo G., Bier D.M., Nosadini R. Models to interpret kinetic data in stable isotope tracer studies. Am J Physiol 1987, 253:E551-E564.
20. Schaefer E.J., McNamara J.R., Asztalos B.F., et al. Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects. Am J Cardiol 2005, 95:1025-1032.
21. Kleemann R., Verschuren L., de Rooij B.J., et al. Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 2004, 103:4188-4194.
22. Arnaud C., Burger F., Steffens S., et al. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol 2005, 25:1231-1236.
23. Mayer C., Gruber H.J., Landl E.M., et al. Rosuvastatin reduces interleukin-6-induced expression of C-reactive protein in human hepatocytes in a STAT3- and C/EBP-dependent fashion. Int J Clin Pharmacol Ther 2007, 45:319-327.
24. Mauger J.F., Levesque J., Paradis M.E., et al. Intravascular kinetics of C-reactive protein and their relationships with features of the metabolic syndrome. J Clin Endocrinol Metab 2008, 93:3158-3164.
25. Lyngdoh T., Vollenweider P., Waeber G., Marques-Vidal P. Association of statins with inflammatory cytokines: a population-based Colaus study. Atherosclerosis 2011.
26. Blackburn P., Despres J.P., Lamarche B., et al. Postprandial variations of plasma inflammatory markers in abdominally obese men. Obesity (Silver Spring) 2006, 14:1747-1754.
27. Gill J.M., Caslake M.J., McAllister C., et al. Effects of short-term detraining on postprandial metabolism, endothelial function, and inflammation in endurance-trained men: dissociation between changes in triglyceride metabolism and endothelial function. J Clin Endocrinol Metab 2003, 88:4328-4335.
28. Manning P.J., Sutherland W.H., Hendry G., de Jong S.A., McGrath M., Williams S.M. Changes in circulating postprandial proinflammatory cytokine concentrations in diet-controlled type 2 diabetes and the effect of ingested fat. Diabetes Care 2004, 27:2509-2511.
29. Nappo F., Esposito K., Cioffi M., et al. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J Am Coll Cardiol 2002, 39:1145-1150.
30. Orban Z., Remaley A.T., Sampson M., Trajanoski Z., Chrousos G.P. The differential effect of food intake and beta-adrenergic stimulation on adipose-derived hormones and cytokines in man. J Clin Endocrinol Metab 1999, 84:2126-2133.
31. Payette C., Blackburn P., Lamarche B., et al. Sex differences in postprandial plasma tumor necrosis factor-alpha, interleukin-6, and C-reactive protein concentrations. Metabolism 2009, 58:1593-1601.
32. Carroll M.F., Schade D.S. Timing of antioxidant vitamin ingestion alters postprandial proatherogenic serum markers. Circulation 2003, 108:24-31.
33. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003, 107:363-369.
34. Thongtang N., Diffenderfer M.R., Ooi E.M., et al. Linkage between C-reactive protein and triglyceride-rich lipoprotein metabolism. Metabolism 2012 Sep 24, pii: S0026-0495(12)00312-5 [Epub ahead of print]. 10.1016/j.metabol.2012.08.008.